



# Genetic and epigenetic re-programming in the progression of inflammatory bowel disease: A comprehensive review

Lahanya Guha<sup>1\*</sup>, Ishfaq Ahmad Bhat<sup>2</sup>

<sup>1</sup>Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Mohali, S.A.S Nagar, Punjab, 160062, India.

<sup>2</sup>Northern Railway Hospital, Sri Mata Vaishno Devi, Katra, Reasi, 182320, India.

### ARTICLE HISTORY

Received: 04-04-2022  
Revised: 05-05-2022  
Accepted: 08-05-2022  
Online: 19-05-2022

### KEYWORDS

Inflammatory bowel disease  
Genetics  
Epigenetics  
DNA methylation  
Micro-RNA (miRNA)  
Ulcerative colitis  
Crohn's disease  
Histone modifications

### ABSTRACT

Inflammatory Bowel Disease (IBD) is portrayed as deleterious and redundant condition. Its point-by-point progression is as yet indistinct, albeit accessible proof proposes that perplexing cooperation between inherited tendencies, ecological variable elements, and contorted and heartless responses are the causes behind the advancement of IBD. Late disclosures concerning its innate characteristics have offered a huge effect on the muddled genetic reason, be that as it may, the perceived innate legacy. The components shed light on the overall contrast in malady. It is bit by bit uncovering itself. It is discernible to say, the epigenetic parts can interpose in the association between genetic characteristics and conditions, leading to accepting an essential job in the progression of the ailment. This review encompasses the late inherited and epigenetic disclosures and jobs in IBD, with consideration regarding epigenetic changes noteworthiness in ineptitude because of illness, development, conduct, and colorectal malignant growth (CRC) and its inert capacity translational applications.

## Introduction

Inflammatory Bowel Disease (IBD) is comprehensively seen as an exceptionally tangled infection with nebulous progression. Ulcerative colitis (UC) and Crohn's disease (CD) are the most comprehensively seen IBD subtypes and

\*Address for correspondence

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Mohali, S.A.S Nagar, Punjab, 160062, India.

Email: [guha.lahanya@gmail.com](mailto:guha.lahanya@gmail.com)

DOI: <https://doi.org/10.55006/biolsciences.2022.2203>

Published by [IR Research Publication](https://irrespub.com); Copyright ©

2022 by Authors is licensed under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/)



dominatingly. impact the gastrointestinal (GI) plot and convey revaluation of the stomach, slow strong releases, upsetting and purulent stools, and weight decline, which generously reduces the individual fulfillment and broadens the financial heap of patients suffering from IBD [1]. Delineated by consistent annoying and wrong safe reactions, IBD can transform into an ailment of stenosis, fistula phenotypes, or even Colorectal carcinoma (CCR), which addresses a real trial of association. Regardless of different huge stretches of assessment, the specific progression has not been clarified. Current information shows that IBD could be seen as the aftereffect of the astounding relationship between acquired propensities, normal fragments, and turned safe reactions [1, 2]. Yet progressing creative progress have a gigantically stimulated genetic screening of IBD, which saw

**Abbreviations:** ASCA: *Anti-Saccharomyces Cerevisiae Antibodies*; CCR: *Colorectal Carcinoma*; CD: *Crohn's Disease*; CDAL: *Crohn's Ailment Development List*; CGRP: *Calcitonin Gene-Related Peptide*; CRC: *Colorectal Cancer*; CRP: *C-Reactive Protein*; DMP: *Differentially methylated position*; DMR: *Differentially Methylated Regions*; DSS: *Dextran Sodium Sulphate*; EMT: *Epithelial-To-Mesenchymal Transition*; ESR: *Erythrocyte Sedimentation Rate*; EWAS: *Epigenome-Wide Methylation Association Studies*; FANCC: *Fanconi Anemia Complementation Group C*; FC: *Faecal Calprotectin*; FRK: *Fyn Related Src Family Tyrosine Kinase*; GDNF: *Glial-Derived Neurotrophic Factor*; GWAS: *Genome-Wide Association Studies* HLA: *Human Leukocyte Antigen*; IBD: *Inflammatory Bowel Disease*; IEC: *Intestinal Epithelial Cells*; IFN: *Interferons*; IL: *Interleukins*; IRGM: *Immunity-related guanosine triphosphatase*; LBP: *Lysozomal Binding Protein*; MDP: *Muramyl Dipeptide*; PIWI: *P-element Induced Wimpy testis*; PTEN: *Phosphatase and tensin homolog*; RARB: *Retinoic Acid Receptor Beta*; RCC: *Renal Cell Carcinoma*; SES: *Simple Endoscopic Score*; TLR: *Toll-Like Receptors*; TNBS: *Trinitrobenzenesulfonic acid*; TNF: *Tumor Necrosis Factor*; UC: *Ulcerative Colitis*; UCEIS: *Ulcerative Colitis Endoscopic Index of Severity*; UTR: *untranslated region*; WES: *Whole-exome sequencing*; WGBS: *Whole-genome bisulfite sequencing*.

innate segments could uncover an understanding of the overall change in the condition [3]. Besides, the surprising complexities in the indications of exacerbation among energetic and more seasoned patients can't be clarified unmistakably by various genotypes; biological elements should in like manner be off due importance on account of the disclosure that ecological changes could shape the verbalization of a despondent person quality through epigenetic gadgets [4]. Additionally, the brisk pace of progression and the incessantly developing system of IBD prompted us to reveal made by interfacing genome conditions in the event and improvement of IBD [5].

Epigenetic devices, e.g., DNA methylation, non-coding RNA, histone interference, and nucleosome repression, basically add to the trade between the genome and the condition [6]. The open test furthermore reinforces essential work on epigenetic wrecks in IBD contamination, weakness, improvement, direct, and CCR, which gave critical encounters into the subatomic explanation of IBD. Also, it is basic that the examination, differential end, ailment affirmation, and treatment of IBD are risky, moreover, starting late, there was emphatically no single reaction to offer an exact assessment and check of the IBD and helped IBD about their preferences [7]. In the hour of drug precision, choosing and treating exactness has become a resolutely tremendous issue in clinical practice as needs to be, the depiction of epigenetic work in IBD offers better ways to deal with push disease representation, treatment, and control. In this investigation, we present acquired and epigenetic revelations in progress in IBD, focusing primarily on epigenetic go after shortcoming to pollution, advancement, lead, CCR, and potential understanding applications [8, 9].

### Timeline of Genetic Research in IBD


Early family tests and twin examinations have exhibited that acquired factors expect an essential activity in the shortcoming of IBD ailment. The patients were fundamentally higher than those in the controls. It should be centered around that foreseen models were obvious. Family members of Disc patients had a higher peril of making an album,

and those patients with CU must be introduced to CU instead of CD [10]. The twin tests have not recently proposed that twins' concordance rates were significantly higher on the album than on UC. Similarly ensured that twins with IBD discussed uncommon consistency in clinical attributes [10, 11]. Coming about assessments concerning holding and union concentrate essentially more saw different IBD fruitlessness loci (IBD1-9). Nucleotides limit the oligomerization space containing 2 (NOD2, in any case, called CARD15) arranged in the IBD1 locus immediately appeared as a Disc risk allele and three extraordinary Single nucleotide polymorphisms (1007FS, G908R, and R702W) were the most assessed [12].

Helbig et al. (2012) watched smoking as a potential modulator for the clarification and work of the NOD2 mRNA, and in this sense, Collaboration to smoke NOD2 (relationship with quality conditions) may acquaint a comprehensive risk with the Compact disc [13]. Mechanical unforeseen developments, for example, the Entire Genome Connection Study (GWAS), totally Exome (WES) sequencing, and exceptional organizing have profoundly stimulated acquired examination in IBD, perceiving more than 241 IBD clumsiness loci including the Interleukin 23 receptor (IL23R), TNF superfamily area 15 (TNFSF15), related to autophagy 16 as 1 (ATG16L1), GTPase M-related insusceptibility (IRGM), Space PR/SET 1 (PRDM1), and spot protein of 52 kDa (NDP52, furthermore called CALCOCO2 [13-15]. This information shows that inborn attributes expect a vocation in the progression of both Disc and UC. In any case, it was incredibly astounding to find that the inheritance presented by hereditary inclination is humbler than foreseen (furthermore called nonattendance of heritage). The accessible information shows that the bit of the inheritance clarified by innate assortments was only 13.1% in Disc, in like manner, 8.2% in UC. Along these lines other components; for example, epigenetic changes are an essential development to reveal the moving progression of IBD [16] (Figure 1).

### Epigenetic Re-programming in IBD


Epigenetic adjustments are portrayed by changes in the acquired phenotype, which can't be clarified by



**Figure 1.** Timeline of genetics research in IBD.

the distinction in DNA helical structure, encompassing epigenetic structures DNA methylation, histone obliteration, and non-coding RNA nucleosomal condition. Some new changes, for example, RNA methylation isn't far away [17]. Among these adjustments, DNA methylation, other than non-coding RNAs is more moved in IBD research. DNA methylation is one of the built changes in DNA. This suggests the covalent expansion of a centralization of methyl in the cytosines, which occurs generally in cytosine phosphate guanine (CpG) dinucleotides, which cause the improvement of 5-methylcytosine [18, 19]. CpG dinucleotides occur in the human genome with a low rehash of 1% and present with non-sporadic apportioning [20] Areas decently collected with CpG dinucleotides are called CpG islands (CGI) that go from 200 bp to 5 kb long, save 1-2% of the genome, and show the decline of transcriptional movement [21]. Some considered having shown crack changes in DNA methylation in patients with IBD [22-25]. Changes in the state of methylation IBD-

related qualities out and out change record levels of nature of improvement and verbalization in this way that structure the infection risk and advancement. Fundamentally, some DNA profiles they broadcast be standard customers on both Album and UC, while others show to be expressed for Disc or UC, which makes the novel. In augmentation, some atypical methylated attributes have been seen related to IBD for the very first time. Non-coding RNAs are a lot of RNA particles that don't change over to proteins, including negligible microRNA (miRNA), prominent RNA (siRNA), accomplice Long non-coding RNA (lncRNA), PIWI RNA (piRNA), and others [26]. Distinctive cell procedures, e.g., interpretation, RNA joining together, quality, and rule also of the chromosomal structure, how DNA replication and genome restriction are related to these Non-coding RNAs [26-28]. Current information shows that it doesn't code RNAs, explicitly miRNAs. It works essentially in untranslated regions '(3' UTR) and 5' UTR of worth, managing the verbalization of significant worth in



**Figure 2.** Epigenetic alteration cascade in the progression of IBD.

both post-transcriptional and transcriptional levels and change of the IBD related structures, e.g., White blood cell parcel, IL23/Th17 stepping, and autophagy pathways; along these lines, influencing the start and improvement of affliction [29-31]. All things considered, it is a central making territory like epigenetic alterations that take on crucial administrative work in quality replication, quality articulation, and chromatin restoration. In this manner, it is to be certain basic to advance moreover endeavors to comment on the limit and instruments of an epigenetic change in IBD. Applying fundamental examination changes over into strong and therapeutic biomarker frameworks moreover becomes essential [32] (Figure 2).

### Role of epigenetics in IBD


Epigenetics could intercede between the hereditary condition and natural components to help to decide the phenotype of many diseases like PCOS, Diabetes, Cancer, etc [33-35]. It is also significantly prevalent in IBD. The exemplary worldview of genotype prompting phenotype and malady has been extended to grasp key etiologic factors in IBD. Epigenetics may associate with both hereditary components and natural variables in influencing the invulnerable framework. The resulting invulnerable

reaction has outcomes on whether abuse is endured or interminable irritation is started and proliferated.

Epigenetic changes are locked in with different ailments, including tumors, neurological improvement issues, cardiovascular diseases, and safe framework sicknesses (rheumatoid joint irritation, IBD, and psoriasis) [36]. Developed elements of epigenetic changes in the development of these diseases propose new destinations for sickness therapy. Also, the basic connection between epigenetic modifications and contamination frailty, development, and lead exhibits a potential ability to investigate and manage the affliction. In this article, we present the elements of epigenetic changes in IBD, with explicit thought concerning DNA methylation and miRNA profiles [37] (Figure 3) (Table 1 and 2).

### Evaluation of ailment action

It is discovered that standard and differential assurance IBD finding relies upon a thorough examination of the office characteristics, research office limits, endoscopy, imaging histological qualities, and tests. Other creating substitutes such as inherited, serological, histological, and fecal markers furthermore showed essential potential in



**Figure 3.** Role of epigenetics in pathogenesis of IBD.

diagnosing afflictions similarly as requested. Disregarding the way that with these procedures, a couple of patients despite everything resolved to have "unclassified IBD" or "questionable colitis. Thusly, the unmistakable evidence of Various definite markers for IBD is totally basic [38].

Epigenetic adjustments, for instance, miRNA and DNA methylation are appealing biomarkers for nuclear assurance. A gigantic number of studies have shown the nature of affectability, unequivocally, and precision in the finding of IBD. Cooke et al. (2012) have convincingly communicated that IBD cases have been shown a couple of changes in mucosal methylation (FANCC, GBGT1, DOK2, THRAP2, and TNFSF4) diverged from sound controls[25]. Moreover, They found a gigantic qualification in the methylation scene among Album and UC patients. For example, patients with Album exhibited FAM10A4, GBGT1, IGFBP4, and hypermethylated IFITM1 appeared differently from patients with CU, which gives a probability to isolate IBD from controls and Disc from UC Therefore, (Adams et al., 2014) suggested that patients with Cd demonstrated various methylation profiles of streaming leukocytes stood out from sound controls [39].

These results agree with a similar disclosure by Cooke et al. They showed that many have perceived the GWAS chance characteristics (ICAM3, CARD9, CDH1, etc.) presented various methylation states among IBD patients (Compact disc and UC) and sound controls, suggesting an opportunity for Unthinking relationship among epigenetic and innate signs [32]. Existing data demonstrated that the nitty-gritty single nucleotide polymorphisms could be arranged in CGI, upset CpG objections, and thusly intrude with CGI methylation states [25]. In the interim, methylation aggravations inside or inside the region to the main record site and the promoter area of shortcoming characteristics furthermore apply an immense impact on quality records [39]. This exhibits genetic danger loci could mediate ramifications for feebleness to contamination through DNA methylation. In 2016, an Epigenome-Wide Affiliation Study (EWAS) of 240 as of late decided adult patients have IBD (Cd and UC) and 190 controls adequately perceived four DMRs like ITGB2, VMP1, CDC42BPB, and WDR8) on Compact disc concerning the controls and two DMRs like WDR8 and VMP1 in UC, concerning controls, which were compared to genomic disclosures that Cd and UC have their focal points shortcoming loci just as shared covering peril loci to some degree [40].

**Table 1.** Roles of DNA methylation in IBD.

<b>Methylated markers</b>	<b>Methylation</b>	<b>Roles</b>	<b>References</b>
<b>Assessment of ailment vulnerability</b>			
ITGB2, FANCC, GBGT1, WDR8, THRAP2	<b>Increased</b>	Crohn's disease affected control vs healthy control	[30],[31]
DOK2, TNFSF4, VMP1	<b>Decreased</b>	Crohn's disease affected control vs healthy control	[30],[31]
THRAP2, CDH1, FANCC, GBGT1, CARD9	<b>Increased</b>	Ulcerative colitis affected control vs healthy control	[30],[31]
ICAM3, DOK2, TNFSF4, VMP1	<b>Decreased</b>	Crohn's disease affected control vs Ulcerative colitis affected control	[21],[30]
GBGT1, IGFBP4, FAM10A4, IFITM1	<b>Increased</b>	Ulcerative colitis affected control vs healthy control	[30]
<b>Cancer Screening</b>			
MLH1, MINT1, SLIT2, HS3ST2, TMEFF2, ITGA4, SYNE1, APC, RUNX3	<b>Increased</b>	Discriminate ulcerative colitis affected control from normal controls	[3],[30]
Cox-2	<b>Decreased</b>	Discriminate ulcerative colitis affected control from normal controls	[30]
miR-137	<b>Increased</b>	Differentiate Colorectal carcinoma and dysplasia from controls	[38]
EYA4, vimentin, BMP3, NDRG4	<b>Increased</b>	Differentiate Colorectal carcinoma and neoplasia from controls	[37]

**Table 2.** Roles of miRNAs in IBD.

<b>miRNAs</b>	<b>Expression levels</b>	<b>Roles</b>	<b>References</b>
miR-21, miR- 16, miR-24, miR-126, miR-151-5p, miR-199a-5p, miR-340*	<b>Decreased</b>	Active vs quiescent ulcerative colitis control	[48],[49]
miRplus- E1271, miR-595	<b>Increased</b>	Active vs quiescent ulcerative colitis control	[48],[49]
miR-124,miR-200b	<b>Increased</b>	Active vs quiescent crohn's disease control	[49],[50]
miR-877,miR-199a-5p, miR-362-3p, miR-532-3p,miR-595	<b>Decreased</b>	Active vs quiescent crohn's disease control	[37],[48],[49],[50]

Starting late, an English investigation bunch revealed unquestionable DNA methylation plans unequivocally to the intestinal area intestinal epithelial cells (IEC) among pediatric patients with IBD and sound controls. Their data indicated that the disease unequivocal DNA IEC (climbing colon) methylation profiles can be definite separate patients with IBD from sound controls with an affectability of 75% and 100% expressed. Also, another ileal methylation association had the choice to perceive Cds from UC with an Exactness of 77% and AUC of 0.92 (affectability of 57%, expressed 100%) [41]. Such a genuine degree of appearance

appraisals recommend its arranged utility in clinical settings. Fruitful usage of DNA methylation markers in the distinctive confirmation of risky tumors e The recognition has opened up new streets for IBD research [42]. Curiously with inherited biomarkers, combined DNA methylation wires, or, on the other hand, unequivocal trademark understanding (e.g., smoking and diet). Furthermore, the impact is old. Similarly, the current affirmation of methylation wraps the tabs of different methylation markers as opposed to a remarkable marker, which shows its predominance in affectivity and qualification [43]. Additionally, DNA methylation biomarkers are

consistent in the circulatory structure, in the tissues, and even in the stool, making it supportive to be saved and perceived. Further, The methylation measures for the individual DNA methylation the mediator will as a rule be wide, which looks like innate markers [44].

Notwithstanding, there are as yet a couple of parts that limit the clinical day-by-day plan. Much equivalent to the bat, as is astounding, the signs of DNA methylation are expressed in the cell. Undeniable evaluation objectives may show stepped separately on DNA methylation profiles on account of various cell types arranged in these objectives. Moreover, immense (45%) unmistakably methylated supporting position (DMP) between UC. Similarly, the Disc may contain additional impediments concerning separation among them [45]. Third, impediments to progress made in DNA methylation assessments confining clinical interpretation The bisulfite-based strategies are the essential frameworks used in this field remain. Awesome models Moreover, the propensity of DNA gathering is difficult. Regardless of the way that the entire bisulfite sequenced genome (WGBS) exhibited central focuses in the test prerequisites, high thought, additionally, less propensity for DNA movement, further undertakings are up 'til now being made. A need is there to choose issues in PCR polymerase and bisulfate change [46]. Furthermore, expensive starter costs must be thought of, which can add to the spending plan examination and hence decay liberal affirmation. DNA methylation markers are a wonderful and promising contraption to make an IBD assessment. Nevertheless, more assessment is required before his clinical application [47].

MicroRNAs (miRNAs) are a pool of non-coding RNAs with a length of around 22 nucleotides, calming of center individual RNA, and quality post-transcriptional verbalization control [48]. Absolute tests have shown a fundamental obligation to the start of affliction and IBD improvement, possible essential outcomes to analyze made by the miRNA considering, and differential end. miRNAs move significantly between IBD and sound control, CD and UC Patients as well as patients who go out and those in incredible states [49]. saw three blood joint miRNA (miRs-3180-3p, miRplus-E1035, and miRplus-F1159), which bestowed differently in patients with dynamic and sound CU controls and could in like manner see patients with an exceptional Compact disc of patients with CU in a practically identical relationship, unequivocal articulation of miRNA [50]. Reduced circle and UC cards were moreover contemplated. CU patients show more significant degrees of miRs-103-2\*, miR-362-3p, and miR-Sound complexities and 532-3p separate, regardless of whether they were

evaporating or in an incredible state. Regardless, patients with Compact disc have constantly exhibited expanded degrees of miR-340 \* in periphery blood. An additional report perceived four express miRNA substitutes (miR-20b, miR-98, miR-125b-1 \*, and let-7e \*) in the colon mucosa. Patients with CU uncovered that they were controlled in the abundance of various occasions differentially inactive UC rather than lethargic UC, Dynamic-Cd, inert Compact disc, and sound controls, coordinating consistent progression in IBD separation attempted the informative furthest reaches of 11 serum miRNAs markers in pediatric CD patients and found that these MiRNA substitutes could carefully detach patients with Compact disc controls with affectability above 80% [51, 52]. Among them saw miRNA, miR-484 has passed a couple of miRNAs and has been promising markers, including open protein C (PCR), against *saccharomyces safe response cerevisiae* (ASCA). Notwithstanding the way that miRNA markers from strip blood and colon mucosa. Grasp critical work in choosing ailments, including work interference, strength, and usage of time, make them unsatisfactory for patients. Salvation miRNA markers can persevere through these insufficiencies and give additional trademark data. Distinctive joint signs of miRNA in spit among IBD cases. Additionally, stable checks can help masters with looking at ailments and get-together [53].

To improve examination exactness, widened tables can be progressively significant. An audit of 76 IBDs Patients (Collection and UC) and 38 number controls were gathered [50]. Clustering models that incorporate a few miRNAs (miR-34b- 3p, miR-377-3p, miR-574-5p, miR-484, and so on.), could be segregated. IBD of strong controls and CD UC, with extended AUC 0.89 to 0.98 and low gathering mistake levels of 3.3% and 3.1%, independently [54]. Even more basically, some analyzing saw broad inclusion of miRNA checks among IBD and other non-delicate issues (principal lupus erythematosus, irritation of the rheumatoid joint, asthma, and so forth.), like genetic inclusion among IBD and other non-touchy issues, which proposed some corresponding ways between them; thusly offers a chance of the progression of data in the assurance and concentrated on IBD treatment [55].

### Assessment of Ailment Vulnerability

A review of the number of occupants in Copenhagen has depicted that about 18% of patients found apathy. 57% experience moderate movement (entirely, not effectively two incidents in the underlying five years, yet not dependably), Likewise, 25% experienced ailments (the illness pulls back each year) during the underlying five years after the Compact disc was completed. UC

connection rates for lethargic, moderate, and the course of the sickness were 13%, 74%, and 13%, freely [56]. As of late lost the faith IBD patients are accessible more genuine danger of result during following for a long time stood out from those with Ensuing sliding. Patients with briefs are prescribed to get microbiology stool examination, and serological tests, e.g., CRP and FSR. To be sure, even sigmoidoscopy or colonoscopy explicitly infers blocking, corrupting, and assessment of the improvement of defilements. Regardless, vital pointers generally don't measure up to the action of the ailment. A couple of patients with the movement of delicate or moderate ailment can show normal serology limits [57]. Saito et al. (2011) examined UC methylation levels of colon patients. They found that the intensified mucosa showed up over totally extended methylation status of glial chose cell separate neurotrophic factor (GDNF) and cadherin 1 (CDH1) loci e calm mucosa As of late, Barnicle et al. (2017) watched DNA methylation plans are on and not stimulated tissues from patients with CU and discovered four contrastingly methylated and declared attributes (ROR1, GXYLT2, RARB e FOXA2) who surrendered to the standard for the bit of Wnt. In like manner, it improves cell motility [58, 59].

Further assessment of 38 IBD patients (29 UC, in like manner, 9 Compact discs) found an essential association between the cutting course methylation of ligand 2 (SLIT2) and histological and endoscopic movement. Between these attributes, the methylation status of multi-steady hindrance 1 (MDR1), where X delicate mental handicap 1 (FMR1), GDNF, and CDH1 quality was raised. Strangely, the methylation status of EPHX1, TNFSF8, CDH17, NOTCH3, PAD14, HOXV2, FRK, etc., lessened in stimulated mucosa regarding calm mucosa, showing that histological profiles of methylation can complete as recognizable operators to overview the advancement of IBD tainting [60]. The association between serum methylation marks and the action of the ailment moreover has. It has been affirmed by some different assessments. Notwithstanding, an advancing genome-wide DNA methylation study has made an opposite derivation that DNA from insignificant blood methylation was not generally phenomenal among dynamic and inactive ailment states [61]. Contemplating the Unfathomable heterogeneity of feeble locales, ailment, tainting, the practices, the degrees of movement of the disease, and the use of medications can affect epigenetic changes, epic expansion, outstandingly composed, exceptional tests are required to affirm the relationship between them further. That should focus on where the most methylated loci have been announced to be loci of IBD shortcoming by GWAS. On the other hand, some methylated loci were from the start perceived in these epigenetic considerations and were demonstrated to be

recalled ahead of time to diminish pennants ways for this sense, and this offered the opportunity to discover new pathogenic pieces of IBD and logically better approaches to manage treatment [58, 62].

The miRNAs were, from the soonest beginning stage, answered as a propelling power in the appraisal of the IBD affliction advancement in 2008. Articulation levels miR-21, miR-16, miR-24, miR-126, and miR-203, are stretched out in one-of-a-kind UC tissues regarding peaceful UC tissues. Rational information shows that patients with dynamic Disc exhibited an all-encompassing joint level of, miR-362-3p, miR-199a-5p, miR-532-3p, and miRplus-E1271, similarly to a reduced assessment of miRplus-F1065, intricacy, and Cd missing patients Subsequently, concerning UC patients, miR-28-5p, miR-151-5p, miR-199a-5p, miR-340 \* and miRplus-E1271, were raised in components, regardless, not torpid. Moreover, miRplus-E1035, miRplus-F1159, and miRs-3180-3p were outlined to pass on differentially in patients with dynamic UC versus dynamic Album. patients, who confirmed the hypothesis that the two subtypes [63, 64].

IBD has been captured in various pathogenic mechanical assemblies. Additional markers for serum or tissue miRNA, e.g., miR-877, miR-595, and miR-124, etc are in a like manner seen as instrumental in separating dynamic IBD from lethargic IBD [65-67]. In 2016, a launcher evaluation of the report exhibited that the movement of miR-223 was not starting late connected with hs-CRP and ESR, yet what's more, related to summary of clinical exercises including Crohn's ailment development list (CDAI), unraveled endoscopic score for Crohn's contamination (SES-Cd), Mayo score, and an endoscopic rundown of ulcerative colitis gravity (UCEIS). Little is known about the assorted prophetic attributes (affectivity, attitude, and AUC) of these miRNAs in recognizing the movement of infection in IBD. Besides, there is still no specific proof of great states of miRNA markers when separated and other Exact markers, e.g., FL, FC, and Serum calprotectin (SC) [68].

### Evaluation of Ailment Characteristics

IBD is a heterogeneous substance with particular illness regions, the season of beginning, phenotypes, and seriousness. A prevailing piece of the patient experience. Remarkable changes in infection rehearse all through the ailment. For instance, some CD patients with combustible phenotypes can change to inflexible phenotypes of penetrating efficiency, and CU patients demonstrating proctitis will transform into expansive colitis as the contamination advances. Some powerful tests suggest that the beginning stage, broad disease, the closeness of the perianal

contamination, and subtypes of stenosis or penetration are inadvertent segments of the dynamic course and exposed anticipation [69]. Screening of patients with a noteworthy less obvious, in the beginning, phase of the infection, is energetically proposed. In this way, It is vital to recognize the markers that can assist specialists in assessing the conduct of the ailment in clinical practice. Tahara et al. (2009b) from the earliest starting point demonstrated that protease was initiated the methylation status of receptor 2 (PAR2) was free identified with various clinical acts of ailment in a review of 84 patients with CU. Their data demonstrated that PAR2 methylation levels when all is said in done would be more prominent in patients with complete colitis viable. Those with rectal colitis and extended methylation levels were likewise associated with steroid and testosterone steroid office phenotypes [70]. Simultaneously, Christerson et al. (2009) Recommended that the arrival of PAR2 could potentiate intestinal myofibroblasts increase and advancement of injuries in patients with CD. While PAR2 is commonly associated with the driving of provocative responses, cell advancement, and injury demeanor in IBD, the PAR2 methylation markers can be finished as a fundamental apparatus in the assessment of the conduct of the contamination [54].

### Cancer Screening

Examination and observation of carcinogenesis are connected with IBD. Trust in a single marker to perceive CRC isn't legitimate, developing sheets intertwining markers of different classes can improve further characteristic exactness. Benderska et al. (2015) demonstrated that merged evaluation of the enunciation profiles ki-67 and miR-26b could decisively recognize 93% of colon danger related to CU. Its application in the gathering of the different times of CRC has in like manner been asserted. Starting late, a Chinese investigation bunch made a blood expository model containing five flowing miRNAs markers (miR-17, miR-15b, miR-26b, miR-21, and miR-145) and CEA, which could viably decide CCR to have an AUC of 0.85, followed by CEA of 0.793 and leading body of five miRNA of 0.681 [71].

Regardless, given the little model size assessment, the feasibility of this definite model must be commonly moved to a greater partner. Mirna substitutes are perceptible, quantifiable, and stable, with high findings and observation execution in isolating CRC from controls. About this, miRNA biomarkers have a high clinical significance. Nevertheless, various miRNA markers are not unequivocal for CRC. Atypical, the explanation structures recognized in CRC are moreover present in various diseases. Moreover, a couple of miRNA

microarray stages and cell types are ought to have been thought of. Notwithstanding the way that the progression of CCR examination and checking is proceeding at a snappy pace, the disclosure and perception of the JRC remain empowering. Perceive more reliable markers and develop they are ending up being more solid illustrative and perception models dynamically crucial Treatment of miRNA capacities in the development and representation of CCR could furthermore improve our understanding CCR will finally improve the idea of perseverance and estimate of the patient [72, 73].

### Functional Study of Epigenetic Modifications in IBD

IBD is a multifactorial disorder achieved by unregulated safe reactions in people without inborn powers. Abnormal immunoregulation and balanced intestinal epithelial limit bizarre autophagy with everything taken into account add to the tangle progression of IBD. A critical confirmation has shown the general effects of epigenetic structures on those relating to IBD hailing valuable changes in pathways, which empowers a better intrinsic understanding e regular factors and supports translation research on epigenetic medicines for IBD victims [74]. Here, are the important effects of epigenetic changes on IBD's most examined pathways and work. Epigenetics will be inspected in the therapeutic comprehension Parcel and revelation of microorganisms from the safety system, the game plan of antigens (affirmation, presentation, and authority), and the creation of cytokines are the most by and large regarded fields of immunoregulation in IBD (Compact disc e UC). The PAR2 initiation demonstrated provocative and calming experts impacts on the colon, advancing taking shape of Type 1 (Th1) T-assistance cell cytokines (IL-1, IFN- $\gamma$ , IL-1, and TNF- $\alpha$ ), Moreover, the presence of the peptide related to the idea of calcitonin (CGRP) autonomously [75, 76]. The most critical degrees of PAR2 methylation are related to genuine phenotypes. From UC (Tahara et al., 2009b), finding that it has assembled bothering and breaking quality gained by PAR2 methylation can cause exceptional CU affliction practices. Also, PAR2 is furthermore compelled by TNF-  $\alpha$  (one of the most gigantic widely appealing individuals on UC and CD), and tangled in cytosolic phospholipase A2 (cPLA2) execution augmentation of intestinal myofibroblasts in Cd patients, following these lines achieve essential work in disposing of Album wounds [21, 43]. RUNX3 is a tumor silencer related to the pathophysiology of IBD and RCC. One of the IBD (Disc Besides, the shortcoming loci is arranged in the chromosomal zone 1p36, where RUNX3 lives [77] (Table 3).

**Table 3.** Functional study of epigenetic modifications in IBD.

Epigenetic Alterations	Functions	References
<b>Immunomodulation</b>		
PAR2	Cytokine and intestinal myo-fibroblast synthesis	[54],[55],[63]
RUNX3	Platelet progression and TNF- $\beta$ downstream pathway control	[64],[65]
IL12B, TRAF-6, HLA-DOB, IL16, THY1, IGHG1	Lymphocyte progression and cytokine response control	[46],[47]
miR-21, miR-155	Partition of T associate cells	[58],[66]
miR-301a, miR-20b, miR-10a, miR-18a, miR-210, miR-223, miR-21	Platelet progression and TNF- $\beta$ downstream pathway control	[68],[69]
<b>Maintaining intestinal epithelial barrier integrity</b>		
MDR1	Disrupts tight junctions and enhances the permeability.	[80]
miR-21	Protects tight junctions and paracellular permeability while preventing intestinal inflammation	[81]

RUNX3 is played unequivocal work on the improvement of Lymphocytes and TNF- $\beta$  hailing pathways related to the progression of UC. Studies have shown that RUNX3 KO mice familiar an over the top response with antigens, on the acceptance of Insusceptible structure microorganisms and unhindered IBD [77, 78]. Thusly, it gives off an impression of being likely that RUNX3 methylation can add to the ridiculous provocative reactions on both Album and UC. Moreover, UC- CRC cases have introduced generously more RUNX3 methylation levels appeared differently concerning UC controls, indicating this RUNX3 agonist can play a reliever and an anticancer work in clinical settings [79] Methylation issues in different attributes (TRAF6, IL12B, HLADOB, IL16, IGHG1, and THY1) furthermore maintained to be so subverted with the improvement of T or B cells or trapped in the antigen the board and reactions of cytokines, which gave motivation to coming about calm presentation [61]. Disregarding DNA methylation, miRNAs are in like manner trapped in particular sorts of immunoregulation identified with IBD. Overexpression of miR-155 intervenes in an inclination towards the Th1 division, while horrible karma miR-155 is slanted to the Th2 segment [51]. Past tests have recommended that the Disc was related to Th17 AND Th1 cytokine structures, while UC was acknowledged to be connected with disturbance hindered by Th2 [80]. The overhead controlled miR-155 applies a glorious ignitable impact to eradicate the case direction Forkhead O3 (FOXO3a). Along these lines, the attestation of provocative cytokines impels, additionally, an IBD-related NF- $\kappa$ B hailing pathway. In any case, a missing

miR-155 shows a monitored impact on measuring colitis by reducing good for blazing creation cytokines (IL-17, IL-6, IL- 12, TNF- $\alpha$ , and IFN- $\gamma$ ), softening the depiction of Immune system microorganisms, and checking the bug splash hindered by Th1 reactions [81].

There is essentially pathophysiology related to CU structures, including the segment of Th2 cells, occurring from Immune system microorganisms non- sensitive reactions, hailing course PTEN/PI3K/Akt e intestinal epithelial cutoff interference [82]. MiR-21 KO mouse with the test. Sodium dextran sulfate colitis (DSS) showed an improvement in block rate and less pestering and injury. Also, miR-21 expects a focal activity in working on the IL23/Th17 center. Late assessments perceived a brisk and positive definitive impact of miR-301a on the Th17 cell segment and the creation of strong provocative cytokines through Down Smad Atomic Interfacing Protein 1 (SNIP1) [83] could be a Promising accommodating mediation for miR-146a Disc patients fuses rule of dendritic cells, Treg cells, and NK cells and hailing pathways identified with NOD2 and Cost like receptors (TLR). Similarly, TLRs are the most crucial parts of the progression of IBD, especially for Albums. NOD2 can see inferred little microorganisms muramyl dipeptide (MDP) and approve caspase 3 and NF- $\kappa$ B checking signs and along these lines conveys steady of combustible bothering cytokines and controls the normal and adaptable bugs of the stomach related bundle [84]. Moreover, it is furthermore associated with keeping the antibacterial edge of the mucosa

organizing the alpha-defensins and beta-defensin articulation [85].

Moreover, a power focused on miR-29 experienced stage II clinical foreplay, to hinder tissue fibrosis. Contrasted with TLRs, TLR4 is extensively executed by lipopolysaccharide (LPS) - a protein that limits LPS (LBP) - CD14 incredible, by then starts the hailing pathway NF- $\kappa$ B e the development of positive for searing cytokines moves [86]. Also, the finish of TLR4 is similarly suggested that NOD2 can change the signs, and NOD2 changes approx effectively made and applied in mouse models of colitis [31]. For example, treatment with miR-155 foes mitigates the reactions to fire in colitis achieved by the DSS mouse model [87]. He et al. (2016) characterized miR-301a antisense oligonucleotide and coordinated in trinitrobenzene ruinous sulfonic destructive (TNBS): colitis model provoked in mice. Along these lines, phenomenal abatement of IL-17A cells and fire star cytokines have been seen in expending tissues. Sporadic, the results assembled in the tests on creatures give a generous rule impetus to translational tests and to make another epigenetics treatment for IBD patients. The impedance of the intestinal epithelial limit is one of the diverse central pathogenic elements for IBD, especially UC [88]. The evidence amassed found that the intestinal epithelium the set up hindrance impacts the protection against organisms attack of microorganisms and colonization, evading poison development and upkeep of safe night out [89, 90]. IBD patients and even people in danger of making IBD could introduce cell hurt intersection point and expanded intestinal porosity. A couple of qualities fuse CDH1, LAMB1, HNF4A, and MYO9B related to the upkeep of epithelial checks. The movement has been reported to have horrendous qualities for UC [91]. The idea of CDH1 exists in the IBD1 locus, and coding E-cadherin mediates the following intersection purposes of colon epithelia. The level of verbalization has decreased and expanded the methylation state was found in the dynamic tissues of CU and CRC, proposing the opportunity of using the CDH1 methylation marker to pack dynamic issues of idle illness and CRC of ground-breaking controls. Close to CDH1, the MDR1 degree also intertwines the infertility loci of UC and is connected with trans-membrane transport and is useful. Intestinal epithelium uphold [92]. Mice missing the mark on the MDR1a quality experienced precipitation like UC intestinal unsettling [93, 94]. Moreover, the joint degrees of MDR1 in mice with DSS-instigated colitis model and UC patients diminished as opposed to sound controls. Expanded methylation levels of MDR1 in provocative tissues contrasted with the solid tissues of patients with CU further affirmed the guarded effects of MDR1 on the digestive system epithelium [95].

## Conclusion

IBD is an amazingly erratic disturbance and addresses a critical test for pros regarding end e calm chiefs. In the hour of precision drugs, we protect this affirmation, treatment, and impression of aggravations. It should be established on individual and phenotypic natural markers, fantastic psychosocial qualities, and perspectives. Important progression has been made in genetic assessment on IBD, with a couple of weaknesses related to IBD. All things considered, the specific. In this sense, miR-301a blockers' natural fragments can simply clarify one little bit of the ailment differentiate when in doubt terms, acquainting the need with reveal made by a couple of parts, for example, epigenetic changes in the event and progress of IBD. Current years have seen great improvement in the epigenetics of IBD, explicitly with a relationship with DNA methylation and miRNA. Intellectual association between epigenetic changes and disorder clumsiness, advancement, direct, and CRC related to IBD has appeared in changed assessments, giving top-down data in the atomic explanation of IBD, and other informative e control instruments for patients with IBD. Some DNA methylations/miRNA-based dashboards for differential finishes and separates appraisal of disorder exercises, and evaluation of sickness rehearse. The affirmation and impression of the CRC were made, with Extraordinary congeniality, attitude, and precision. Epigenetic markers are further signs to choose the fixes methodology and wanting for a supportive reaction. Given basic duties regarding IBD, pharmacological adjustment of epigenetic adventures offers opportunities for reconstructing understanding for future clinical applications. Nevertheless, current clinical foreplay or preclinical foreplay revolves around risky advancement treatment and secure some basic results, by researching the understanding capacity of the related epigenetic modifications of IBD, the evaluation of IBD is persistent in its starting stages and there are as yet a couple of difficulties to go up against. More associations are required to see show old-style epigenetic middle people and climbing markers, additionally, to powerfully develop separate and enthusiastic control cards containing various types of bookmarks. Consistent undertakings must be made to develop essentially in a profitable way moreover, express treatment, see goals and focal points effects of epigenetic changes, improve transport advances for miRNAs, and explains the common impacts of intestinal microbiota in epigenetic plans. Also, considering that the histone changes and that the nucleosome is discovered e other non-coding RNAs, for example, lncRNA piRNA, and siRNA are less pressed in IBD, further undertakings should consolidate created by these epigenetic changes in the progression of IBD. Thusly, one can reason well on this. Epigenetics has

a central activity in the progression of IBD. It moreover has an affirmation for the confirmation and impression of diseases on chance conjecture and revamping improvement.

### Contribution of authors

All the authors have contributed equally to designing, drafting, writing, and analyzing the manuscript.

### Acknowledgments

I would like to thank Ishfaq Ahmed Bhat for guiding me preparing the manuscript. I, Lahanya Guha have made the manuscript, prepared all the images and tables and inserted citations.

### Conflict of interest

The authors declare no conflict of interest, financial or otherwise.

### References

1. A. Kaser, S. Zeissig, and R. S. Blumberg, "Inflammatory bowel disease," (in eng), *Annual review of immunology*, vol. 28, pp. 573-621, 2010, doi: 10.1146/annurev-immunol-030409-101225.
2. H. Zhang, Z. Zeng, A. Mukherjee, and B. Shen, "Molecular diagnosis and classification of inflammatory bowel disease," (in eng), *Expert review of molecular diagnostics*, vol. 18, no. 10, pp. 867-886, Oct 2018, doi: 10.1080/14737159.2018.1516549.
3. N. T. Ventham, N. A. Kennedy, E. R. Nimmo, and J. Satsangi, "Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics," (in eng), *Gastroenterology*, vol. 145, no. 2, pp. 293-308, Aug 2013, doi: 10.1053/j.gastro.2013.05.050.
4. K. Aleksandrova, B. Romero-Mosquera, and V. Hernandez, "Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention," (in eng), *Nutrients*, vol. 9, no. 9, Aug 30 2017, doi: 10.3390/nu9090962.
5. G. G. Kaplan and S. C. Ng, "Understanding and Preventing the Global Increase of Inflammatory Bowel Disease," (in eng), *Gastroenterology*, vol. 152, no. 2, pp. 313-321.e2, Feb 2017, doi: 10.1053/j.gastro.2016.10.020.
6. P. S. Karatzas, M. Gazouli, M. Safioleas, and G. J. Mantzaris, "DNA methylation changes in inflammatory bowel disease," (in eng), *Annals of gastroenterology*, vol. 27, no. 2, pp. 125-132, 2014.
7. J. S. Levine and R. Burakoff, "Extraintestinal manifestations of inflammatory bowel disease," *Gastroenterology & hepatology*, vol. 7, no. 4, p. 235, 2011.
8. W. Li, "Precision medicine: to cure and relieve more," *Precision Clinical Medicine*, vol. 1, no. 1, pp. 3-4, 2018, doi: 10.1093/pcmedi/pby002 %J Precision Clinical Medicine.
9. S. M. Weissman, "Personalized medicine: a new horizon for medical therapy," *Precision Clinical Medicine*, vol. 1, no. 1, pp. 1-2, 2018, doi: 10.1093/pcmedi/pby001 %J Precision Clinical Medicine.
10. J. Satsangi, D. P. Jewell, W. M. Rosenberg, and J. I. Bell, "Genetics of inflammatory bowel disease," (in eng), *Gut*, vol. 35, no. 5, pp. 696-700, May 1994, doi: 10.1136/gut.35.5.696.
11. J. Halfvarson, L. Bodin, C. Tysk, E. Lindberg, and G. Järnerot, "Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics," (in eng), *Gastroenterology*, vol. 124, no. 7, pp. 1767-73, Jun 2003, doi: 10.1016/s0016-5085(03)00385-8.
12. T. Ahmad, J. Satsangi, D. McGovern, M. Bunce, and D. P. Jewell, "Review article: the genetics of inflammatory bowel disease," (in eng), *Alimentary pharmacology & therapeutics*, vol. 15, no. 6, pp. 731-48, Jun 2001, doi: 10.1046/j.1365-2036.2001.00981.x.
13. K. L. Helbig et al., "A case-only study of gene-environment interaction between genetic susceptibility variants in NOD2 and cigarette smoking in Crohn's disease aetiology," (in eng), *BMC medical genetics*, vol. 13, p. 14, Mar 14 2012, doi: 10.1186/1471-2350-13-14.
14. D. Ellinghaus et al., "Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies," (in eng), *Gastroenterology*, vol. 145, no. 2, pp. 339-47, Aug 2013, doi: 10.1053/j.gastro.2013.04.040.
15. J. Z. Liu et al., "Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations," (in eng), *Nature genetics*, vol. 47, no. 9, pp. 979-986, Sep 2015, doi: 10.1038/ng.3359.
16. K. M. de Lange et al., "Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease," (in eng),

- Nature genetics, vol. 49, no. 2, pp. 256-261, Feb 2017, doi: 10.1038/ng.3760.
17. H. Huang et al., "Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally," (in eng), *Nature*, vol. 567, no. 7748, pp. 414-419, Mar 2019, doi: 10.1038/s41586-019-1016-7.
  18. A. Jeltsch, J. Broche, and P. Bashtrykov, "Molecular Processes Connecting DNA Methylation Patterns with DNA Methyltransferases and Histone Modifications in Mammalian Genomes," (in eng), *Genes*, vol. 9, no. 11, Nov 21 2018, doi: 10.3390/genes9110566.
  19. L. Li, K. Fu, W. Zhou, and M. Snyder, "Applying circulating tumor DNA methylation in the diagnosis of lung cancer," *Precision Clinical Medicine*, vol. 2, no. 1, pp. 45-56, 2019, doi: 10.1093/pcmedi/pbz003 %J Precision Clinical Medicine.
  20. A. Portela and M. Esteller, "Epigenetic modifications and human disease," (in eng), *Nature biotechnology*, vol. 28, no. 10, pp. 1057-68, Oct 2010, doi: 10.1038/nbt.1685.
  21. W. Y. Tang and S. M. Ho, "Epigenetic reprogramming and imprinting in origins of disease," (in eng), *Reviews in endocrine & metabolic disorders*, vol. 8, no. 2, pp. 173-82, Jun 2007, doi: 10.1007/s11154-007-9042-4.
  22. T. Tahara et al., "Effect of MDR1 gene promoter methylation in patients with ulcerative colitis," (in eng), *International journal of molecular medicine*, vol. 23, no. 4, pp. 521-7, Apr 2009, doi: 10.3892/ijmm\_00000160.
  23. E. McDermott et al., "DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis," (in eng), *Journal of Crohn's & colitis*, vol. 10, no. 1, pp. 77-86, Jan 2016, doi: 10.1093/ecco-jcc/jjv176.
  24. K. Kang, J. H. Bae, K. Han, E. S. Kim, T. O. Kim, and J. M. Yi, "A Genome-Wide Methylation Approach Identifies a New Hypermethylated Gene Panel in Ulcerative Colitis," (in eng), *International journal of molecular sciences*, vol. 17, no. 8, Aug 9 2016, doi: 10.3390/ijms17081291.
  25. J. Cooke et al., "Mucosal genome-wide methylation changes in inflammatory bowel disease," (in eng), *Inflammatory bowel diseases*, vol. 18, no. 11, pp. 2128-37, Nov 2012, doi: 10.1002/ibd.22942.
  26. T. Gutschner and S. Diederichs, "The hallmarks of cancer: a long non-coding RNA point of view," (in eng), *RNA biology*, vol. 9, no. 6, pp. 703-19, Jun 2012, doi: 10.4161/rna.20481.
  27. Y. Dong et al., "Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy," (in eng), *International journal of biological sciences*, vol. 14, no. 9, pp. 1133-1141, 2018, doi: 10.7150/ijbs.26215.
  28. J. Wehkamp et al., "NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression," (in eng), *Gut*, vol. 53, no. 11, pp. 1658-64, Nov 2004, doi: 10.1136/gut.2003.032805.
  29. J. E. Wilusz, H. Sunwoo, and D. L. Spector, "Long noncoding RNAs: functional surprises from the RNA world," (in eng), *Genes & development*, vol. 23, no. 13, pp. 1494-504, Jul 1 2009, doi: 10.1101/gad.1800909.
  30. J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, "Many roads to maturity: microRNA biogenesis pathways and their regulation," (in eng), *Nature cell biology*, vol. 11, no. 3, pp. 228-34, Mar 2009, doi: 10.1038/ncb0309-228.
  31. R. Kalla et al., "MicroRNAs: new players in IBD," (in eng), *Gut*, vol. 64, no. 3, pp. 504-17, Mar 2015, doi: 10.1136/gutjnl-2014-307891.
  32. Z. Zeng, A. Mukherjee, and H. Zhang, "From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease," (in eng), *Frontiers in genetics*, vol. 10, p. 1017, 2019, doi: 10.3389/fgene.2019.01017.
  33. Z. Rahman, M. R. Bazaz, T. Pasam, M. S. Kumar, and M. P. Dandekar, "Importance of biological clock epigenetics in the manifestation of polycystic ovary syndrome," *Biological Sciences*, vol. 1, no. 1, pp. 67-81, 2021.
  34. C. Ling and T. Rönn, "Epigenetics in Human Obesity and Type 2 Diabetes," (in eng), *Cell Metab*, vol. 29, no. 5, pp. 1028-1044, 2019, doi: 10.1016/j.cmet.2019.03.009.
  35. S. Sharma, T. K. Kelly, and P. A. Jones, "Epigenetics in cancer," (in eng), *Carcinogenesis*, vol. 31, no. 1, pp. 27-36, 2010, doi: 10.1093/carcin/bgp220.
  36. N. Jawad, N. Direkze, and S. J. Leedham, "Inflammatory bowel disease and colon cancer," (in eng), *Recent Results Cancer Res*, vol. 185, pp. 99-115, 2011, doi: 10.1007/978-3-642-03503-6\_6.
  37. D. E. Handy, R. Castro, and J. Loscalzo, "Epigenetic modifications: basic mechanisms and role in cardiovascular disease," (in eng), *Circulation*, vol. 123, no. 19, pp. 2145-2156, 2011, doi: 10.1161/CIRCULATIONAHA.110.956839.
  38. J. Satsangi, M. S. Silverberg, S. Vermeire, and J. F. Colombel, "The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications," (in eng), *Gut*, vol. 55, no. 6,

- pp. 749-53, Jun 2006, doi: 10.1136/gut.2005.082909.
39. A. T. Adams et al., "Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci," (in eng), *Inflammatory bowel diseases*, vol. 20, no. 10, pp. 1784-93, Oct 2014, doi: 10.1097/mib.000000000000179.
  40. Y. Dai, G. Pei, Z. Zhao, and P. Jia, "A Convergent Study of Genetic Variants Associated With Crohn's Disease: Evidence From GWAS, Gene Expression, Methylation, eQTL and TWAS," (in English), *Frontiers in genetics*, Original Research vol. 10, 2019-April-09 2019, doi: 10.3389/fgene.2019.00318.
  41. K. J. Howell et al., "DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome," (in eng), *Gastroenterology*, vol. 154, no. 3, pp. 585-598, Feb 2018, doi: 10.1053/j.gastro.2017.10.007.
  42. W. J. Locke et al., "DNA Methylation Cancer Biomarkers: Translation to the Clinic," (in eng), *Frontiers in genetics*, vol. 10, pp. 1150-1150, 2019, doi: 10.3389/fgene.2019.01150.
  43. P. W. Laird, "The power and the promise of DNA methylation markers," (in eng), *Nature reviews. Cancer*, vol. 3, no. 4, pp. 253-66, Apr 2003, doi: 10.1038/nrc1045.
  44. J. R. Raut, Z. Guan, P. Schrotz-King, and H. Brenner, "Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review," *Clinical Epigenetics*, vol. 12, no. 1, p. 122, 2020/08/10 2020, doi: 10.1186/s13148-020-00904-7.
  45. J. M. Whyte, J. J. Ellis, M. A. Brown, and T. J. Kenna, "Best practices in DNA methylation: lessons from inflammatory bowel disease, psoriasis and ankylosing spondylitis," *Arthritis Research & Therapy*, vol. 21, no. 1, p. 133, 2019/06/03 2019, doi: 10.1186/s13075-019-1922-y.
  46. A. Raine, E. Manlig, P. Wahlberg, A. C. Syvänen, and J. Nordlund, "SPLinted Ligation Adapter Tagging (SPLAT), a novel library preparation method for whole genome bisulphite sequencing," (in eng), *Nucleic acids research*, vol. 45, no. 6, p. e36, Apr 7 2017, doi: 10.1093/nar/gkw1110.
  47. O. Taryma-Leśniak, K. E. Sokolowska, and T. K. Wojdacz, "Current status of development of methylation biomarkers for in vitro diagnostic IVD applications," *Clinical Epigenetics*, vol. 12, no. 1, p. 100, 2020/07/06 2020, doi: 10.1186/s13148-020-00886-6.
  48. K. Fisher and J. Lin, "MicroRNA in inflammatory bowel disease: Translational research and clinical implication," (in eng), *World journal of gastroenterology*, vol. 21, no. 43, pp. 12274-82, Nov 21 2015, doi: 10.3748/wjg.v21.i43.12274.
  49. F. Wu et al., "Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease," (in eng), *Inflammatory bowel diseases*, vol. 17, no. 1, pp. 241-50, Jan 2011, doi: 10.1002/ibd.21450.
  50. C. G. Chapman and J. Pekow, "The emerging role of miRNAs in inflammatory bowel disease: a review," (in eng), *Therapeutic advances in gastroenterology*, vol. 8, no. 1, pp. 4-22, Jan 2015, doi: 10.1177/1756283x14547360.
  51. M. Coskun, J. T. Bjerrum, J. B. Seidelin, J. T. Troelsen, J. Olsen, and O. H. Nielsen, "miR-20b, miR-98, miR-125b-1\*, and let-7e\* as new potential diagnostic biomarkers in ulcerative colitis," (in eng), *World journal of gastroenterology*, vol. 19, no. 27, pp. 4289-99, Jul 21 2013, doi: 10.3748/wjg.v19.i27.4289.
  52. A. M. Zahm, M. Thayu, N. J. Hand, A. Horner, M. B. Leonard, and J. R. Friedman, "Circulating microRNA is a biomarker of pediatric Crohn disease," (in eng), *Journal of pediatric gastroenterology and nutrition*, vol. 53, no. 1, pp. 26-33, Jul 2011, doi: 10.1097/MPG.0b013e31822200cc.
  53. J. S. Schaefer et al., "MicroRNA signatures differentiate Crohn's disease from ulcerative colitis," (in eng), *BMC immunology*, vol. 16, p. 5, Feb 10 2015, doi: 10.1186/s12865-015-0069-0.
  54. U. Christerson, A. V. Keita, J. D. Söderholm, and C. Gustafson-Svärd, "Potential role of protease-activated receptor-2-stimulated activation of cytosolic phospholipase A(2) in intestinal myofibroblast proliferation: Implications for stricture formation in Crohn's disease," (in eng), *Journal of Crohn's & colitis*, vol. 3, no. 1, pp. 15-24, Feb 2009, doi: 10.1016/j.crohns.2008.10.002.
  55. C. W. Lees, J. C. Barrett, M. Parkes, and J. Satsangi, "New IBD genetics: common pathways with other diseases," (in eng), *Gut*, vol. 60, no. 12, pp. 1739-53, Dec 2011, doi: 10.1136/gut.2009.199679.
  56. T. Jess et al., "Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark," (in eng), *Inflammatory bowel diseases*, vol. 13, no. 4, pp. 481-9, Apr 2007, doi: 10.1002/ibd.20036.

57. F. Magro et al., "Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders," (in eng), *Journal of Crohn's & colitis*, vol. 11, no. 6, pp. 649-670, Jun 1 2017, doi: 10.1093/ecco-jcc/jjx008.
58. S. Saito et al., "DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status," (in eng), *Inflammatory bowel diseases*, vol. 17, no. 9, pp. 1955-65, Sep 2011, doi: 10.1002/ibd.21573.
59. A. Barnicle, C. Seoighe, J. M. Grealley, A. Golden, and L. J. Egan, "Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis," (in eng), *Epigenetics*, vol. 12, no. 8, pp. 591-606, Aug 2017, doi: 10.1080/15592294.2017.1334023.
60. T. Lobatón et al., "Relationship between methylation and colonic inflammation in inflammatory bowel disease," (in eng), *World journal of gastroenterology*, vol. 20, no. 30, pp. 10591-8, Aug 14 2014, doi: 10.3748/wjg.v20.i30.10591.
61. N. J. Gould, K. L. Davidson, C. U. Nwokolo, and R. P. Arasaradnam, "A systematic review of the role of DNA methylation on inflammatory genes in ulcerative colitis," (in eng), *Epigenomics*, vol. 8, no. 5, pp. 667-84, May 2016, doi: 10.2217/epi-2016-0006.
62. Z. Lin et al., "Identification of disease-associated DNA methylation in B cells from Crohn's disease and ulcerative colitis patients," (in eng), *Digestive diseases and sciences*, vol. 57, no. 12, pp. 3145-53, Dec 2012, doi: 10.1007/s10620-012-2288-z.
63. J. Hanna, G. S. Hossain, and J. Kocerha, "The Potential for microRNA Therapeutics and Clinical Research," (in English), *Frontiers in genetics*, Mini Review vol. 10, 2019-May-16 2019, doi: 10.3389/fgene.2019.00478.
64. F. E. Ahmed et al., "Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle," (in eng), *Cancer Genomics Proteomics*, vol. 10, no. 3, pp. 93-113, May-Jun 2013.
65. M. Iborra et al., "Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease," (in eng), *Clinical and experimental immunology*, vol. 173, no. 2, pp. 250-8, Aug 2013, doi: 10.1111/cei.12104.
66. G. Koukos et al., "MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis," (in eng), *Gastroenterology*, vol. 145, no. 4, pp. 842-52.e2, Oct 2013, doi: 10.1053/j.gastro.2013.07.001.
67. G. W. Krissansen et al., "Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease," (in eng), *Inflammatory bowel diseases*, vol. 21, no. 3, pp. 520-30, Mar 2015, doi: 10.1097/mib.000000000000285.
68. H. Wang et al., "Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease," (in eng), *Medicine*, vol. 95, no. 5, p. e2703, Feb 2016, doi: 10.1097/md.0000000000002703.
69. F. Gomollón et al., "3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management," (in eng), *Journal of Crohn's & colitis*, vol. 11, no. 1, pp. 3-25, Jan 2017, doi: 10.1093/ecco-jcc/jjw168.
70. T. Tahara et al., "Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC)," (in eng), *Clinical and experimental medicine*, vol. 9, no. 2, pp. 125-30, Jun 2009, doi: 10.1007/s10238-008-0025-x.
71. N. Benderska et al., "miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis," (in eng), *Inflammatory bowel diseases*, vol. 21, no. 9, pp. 2039-51, Sep 2015, doi: 10.1097/mib.0000000000000453.
72. J. R. Pekow et al., "miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes," (in eng), *Inflammatory bowel diseases*, vol. 18, no. 1, pp. 94-100, Jan 2012, doi: 10.1002/ibd.21742.
73. K. Ludwig et al., "PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis," (in eng), *Virchows Archiv : an international journal of pathology*, vol. 462, no. 1, pp. 57-63, Jan 2013, doi: 10.1007/s00428-012-1345-5.
74. A. E. M'Koma, "The multifactorial etiopathogenesis interplay of inflammatory bowel disease: an overview," *Gastrointestinal Disorders*, vol. 1, no. 1, pp. 75-105, 2018.
75. S. Fiorucci et al., "Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis," (in eng), *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 24, pp. 13936-41, Nov 20 2001, doi: 10.1073/pnas.241377298.

76. N. Cenac et al., "Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2," (in eng), *The American journal of pathology*, vol. 161, no. 5, pp. 1903-15, Nov 2002, doi: 10.1016/s0002-9440(10)64466-5.
77. O. Brenner et al., "Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia," (in eng), *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 45, pp. 16016-21, Nov 9 2004, doi: 10.1073/pnas.0407180101.
78. M. M. Garrity-Park, E. V. Loftus, Jr., S. C. Bryant, and T. C. Smyrk, "A Biomarker Panel to Detect Synchronous Neoplasm in Non-neoplastic Surveillance Biopsies from Patients with Ulcerative Colitis," (in eng), *Inflammatory bowel diseases*, vol. 22, no. 7, pp. 1568-74, Jul 2016, doi: 10.1097/mib.0000000000000789.
79. M. M. Garrity-Park, E. V. Loftus, Jr., W. J. Sandborn, S. C. Bryant, and T. C. Smyrk, "Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer," (in eng), *The American journal of gastroenterology*, vol. 105, no. 7, pp. 1610-9, Jul 2010, doi: 10.1038/ajg.2010.22.
80. S. Brand, "Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease," (in eng), *Gut*, vol. 58, no. 8, pp. 1152-67, Aug 2009, doi: 10.1136/gut.2008.163667.
81. J. Wan, L. Xia, W. Xu, and N. Lu, "Expression and Function of miR-155 in Diseases of the Gastrointestinal Tract," (in eng), *International journal of molecular sciences*, vol. 17, no. 5, May 11 2016, doi: 10.3390/ijms17050709.
82. S. Moein, M. Vaghari-Tabari, D. Qujeq, M. Majidinia, S. M. Nabavi, and B. Yousefi, "MiRNAs and inflammatory bowel disease: An interesting new story," (in eng), *Journal of cellular physiology*, vol. 234, no. 4, pp. 3277-3293, Apr 2019, doi: 10.1002/jcp.27173.
83. M. Lucafò et al., "Pharmacogenetics of treatments for inflammatory bowel disease," (in eng), *Expert opinion on drug metabolism & toxicology*, vol. 14, no. 12, pp. 1209-1223, Dec 2018, doi: 10.1080/17425255.2018.1551876.
84. B. J. Kullberg et al., "Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli," (in eng), *Immunology*, vol. 123, no. 4, pp. 600-5, Apr 2008, doi: 10.1111/j.1365-2567.2007.02735.x.
85. E. Voss, J. Wehkamp, K. Wehkamp, E. F. Stange, J. M. Schröder, and J. Harder, "NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2," (in eng), *The Journal of biological chemistry*, vol. 281, no. 4, pp. 2005-11, Jan 27 2006, doi: 10.1074/jbc.M511044200.
86. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, and F. Gusovsky, "Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction," (in eng), *The Journal of biological chemistry*, vol. 274, no. 16, pp. 10689-92, Apr 16 1999, doi: 10.1074/jbc.274.16.10689.
87. Z. J. Lu et al., "MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression," (in eng), *World journal of gastroenterology*, vol. 23, no. 6, pp. 976-985, Feb 14 2017, doi: 10.3748/wjg.v23.i6.976.
88. C. He et al., "miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF- $\alpha$  in IBD," (in eng), *Gut*, vol. 65, no. 12, pp. 1938-1950, Dec 2016, doi: 10.1136/gutjnl-2015-309389.
89. A. Latiano et al., "The association of MYO9B gene in Italian patients with inflammatory bowel diseases," (in eng), *Alimentary pharmacology & therapeutics*, vol. 27, no. 3, pp. 241-8, Feb 1 2008, doi: 10.1111/j.1365-2036.2007.03551.x.
90. J. C. Barrett et al., "Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region," (in eng), *Nature genetics*, vol. 41, no. 12, pp. 1330-4, Dec 2009, doi: 10.1038/ng.483.
91. V. M. Wolters et al., "Replication of genetic variation in the MYO9B gene in Crohn's disease," (in eng), *Human immunology*, vol. 72, no. 7, pp. 592-7, Jul 2011, doi: 10.1016/j.humimm.2011.03.025.
92. P. Azarschab, R. Porschen, M. Gregor, N. Blin, and K. Holzmann, "Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis," (in eng), *Genes Chromosomes Cancer*, vol. 35, no. 2, pp. 121-6, Oct 2002, doi: 10.1002/gcc.10101.
93. C. M. Panwala, J. C. Jones, and J. L. Viney, "A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis," (in eng), *Journal of immunology (Baltimore, Md. : 1950)*, vol. 161, no. 10, pp. 5733-44, Nov 15 1998. [Online]. Available:

<https://www.jimmunol.org/content/jimmunol/161/10/5733.full.pdf>.

94. G. T. Ho, D. R. Gaya, and J. Satsangi, "Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player?," (in eng), *Inflammatory bowel diseases*, vol. 11, no. 11, pp. 1013-9, Nov 2005, doi: 10.1097/01.mib.0000186488.53493.c3.
95. T. Tahara et al., "DNA methylation status of epithelial-mesenchymal transition (EMT)--related genes is associated with severe clinical phenotypes in ulcerative colitis (UC)," (in eng), *PloS one*, vol. 9, no. 10, p. e107947, 2014, doi: 10.1371/journal.pone.0107947.